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Abstract
Objective: Pre-treatment with angiotensin receptor blockers is known to improve neurological outcome after stroke. This
study investigated for the first time, whether the renin inhibitor aliskiren has similar neuroprotective effects.
Methods: Since aliskiren specifically blocks human renin, double transgenic rats expressing human renin and
angiotensinogen genes were used. To achieve a systolic blood pressure of 150 or 130 mmHg animals were treated with
aliskiren (7.5 or 12.5 mg/kg*d) or candesartan (1.5 or 10 mg/kg*d) via osmotic minipump starting five days before middle
cerebral artery occlusion with reperfusion. Infarct size was determined by magnetic resonance imaging. mRNA of
inflammatory marker genes was studied in different brain regions.
Results: The mortality of 33.3% (7 of 21 animals) in the vehicle group was reduced to below 10% by treatment with
candesartan or aliskiren (p,0.05). Aliskiren-treated animals had a better neurological outcome 7 days post-ischemia,
compared to candesartan (Garcia scale: 9.960.7 vs. 7.360.7; p,0.05). The reduction of infarct size in the aliskiren group did
not reach statistical significance compared to candesartan and vehicle (24 h post-ischemia: 314681 vs. 377670 and
403670 mm
3 respectively). Only aliskiren was able to significantly reduce stroke-induced gene expression of CXC
chemokine ligand 1, interleukin-6 and tumor necrosis factor-alpha in the ischemic core.
Conclusions: Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least
as effective as candesartan in double transgenic rats. The improved neurological outcome in the aliskiren group was blood
pressure independent. Whether this effect is due to primary anti-inflammatory mechanisms has to be investigated further.
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Introduction
Aliskiren is a potent and selective renin inhibitor that blocks the
first and rate limiting enzymatic step of angiotensin generation.
Preclinical and clinical studies demonstrated the effectiveness of
aliskiren for blood pressure reduction and tissue protection [1–4].
Its antihypertensive efficacy is comparable to that of angiotensin
receptor blockers [5]. In previous studies we demonstrated that
pre-treatment with angiotensin receptor blockers in rats improved
neurological outcome and reduced infarct size after cerebral
ischemia, induced by middle cerebral artery occlusion with
reperfusion (MCAOR) [6–10]. It is unknown so far, whether a
similar effect might be reached by direct renin inhibition.
Candesartan blocks the angiotensin type 1 receptor. In contrast,
renin inhibition limits the generation of angiotensin II and thus
reduces the activation of both angiotensin type 1 and type 2
receptors. Negative effects might arise, since a protective role of
the angiotensin type 2 receptor is under discussion [11,12].
Candesartan is known to pass the blood-brain barrier even in
healthy animals [13]. There are no such data published for
aliskiren, however, after cerebral ischemia the permeability of the
blood-brain barrier is strongly increased [14].
The aim of the present study was to investigate the putative
neuroprotective effects of systemic pre-treatment with aliskiren in
comparison to candesartan in a hypertensive animal model of
cerebral ischemia, regarding mortality, neurological outcome,
infarct volume and inflammatory gene regulation in brain tissue.
Since aliskiren specifically blocks human renin, this study was
carried out in double transgenic rats (dTGR) expressing human
renin and human angiotensinogen genes as described previously
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15052[15]. dTGR develop hypertension with severe organ damage and
do not live beyond the eighth week of age. It is known, that in
dTGR aliskiren has antihypertensive and anti-inflammatory effects
and protects from end-organ damage [16–18]. Effects of aliskiren
on cerebral ischemia have not yet been investigated.
Methods
Ethics statement
Animals were treated according to national rules and regula-
tions. The local animal welfare office (Landesamt fu ¨r Gesundheit
und Soziales, Berlin) formally approved this study (Permit
Number: G0035/06). All efforts were taken to ameliorate any
suffering.
Animals and study protocol
dTGR (5–6 weeks of age, 125–135g; provided by Dominik N.
Mueller) were maintained under specific pathogen-free controlled
conditions (2062uC, 12 h light/dark cycle) with free access to food
and water. Preliminary dose-finding experiments were carried out
to identify doses of candesartan and aliskiren that result in a
systolic blood pressure (SBP) of 150 or 130 mmHg after 5 days of
treatment. Those doses were 1.5 or 10 mg/kg*d for candesartan
and 7.5 or 12.5 mg/kg*d for aliskiren. Animals were randomly
assigned to the following treatment groups: sham vehicle; sham
candesartan; sham aliskiren; MCAOR vehicle; MCAOR cande-
sartan and MCAOR aliskiren. Animals were either pre-treated to
a SBP of 150 mmHg starting 5 days prior to MCAOR with
subsequent follow-up of 24 h (protocol 1) or pre–treated more
intensively to a SBP of 130 mmHg with follow-up of 7 days
(protocol 2). The latter protocol did not comprise vehicle groups,
because untreated dTGR do not survive 48 h after MCAOR.
Subcutaneous osmotic minipumps (Alzet, Cupertino, CA, USA)
for administration of drugs or vehicle were implanted five days
before MCAOR (or sham intervention). The minipumps released
the drugs continuously until study end. SBP was measured before
implantation of the minipumps and before MCAOR by tail
plethysmography as described previously [19]. Neurological
evaluation was carried out before implantation of minipumps,
before MCAOR and 24 h, 48 h and 7 days post-ischemia. Infarct
size was evaluated by magnetic resonance imaging 24 h and 7
days after MCAOR. Animals were decapitated 24 h (protocol 1)
or 7 days (protocol 2) after MCAOR in final anesthesia. Brains
were removed immediately, weighed and stored at 280uC.
Middle cerebral artery occlusion with reperfusion
(MCAOR)
Focal cerebral ischemia was induced by right MCAOR for
90 min as described previously by our group [20–23]. Briefly,
under general anesthesia the right cervical carotid bifurcation was
exposed through a midline neck incision. A silicon-coated nylon
monofilament was inserted through the proximal external carotid
artery into the internal carotid artery and finally into the middle
cerebral artery. After 90 minutes the filament was withdrawn to
allow reperfusion. Sham-operated rats underwent the same
surgical procedures except the occluding monofilament. Animals
that did not survive this procedure were excluded from the study.
Neurological score
Neurological evaluation was performed by a blinded observer
according to a well-established neurological scoring system
consisting of 6 items: spontaneous activity, symmetry of limb
movement, forepaw outstretching, climbing, body proprioception
and response to vibrissae touch [24]. Each item was graded from 0
(severe deficit) to 3 (no deficit). The gradings of all 6 items were
added. The resulting score for each animal can reach a maximum
of 18 points.
Quantification of infarct volume by magnetic resonance
imaging
Magnetic resonance imaging has become an accepted standard
for testing neuroprotective drugs in the setting of stroke in animals
[25]. Measurements were done on a 7 Tesla Bruker PharmaScan
70/16 with a gradient of 120 mT/m using a
1H-RF volume
resonator with an inner diameter of 38 mm (Bruker BioSpin
Corp., Billericia, MA, USA). The system was interfaced to a Linux
PC running ParaVision 4.0. Isoflurane anesthesia was controlled
using a small animal monitoring and gating system (SA
Instruments, Stony Brook, New York, USA). For imaging a T2-
weighted 2D turbo spin-echo sequence was used (TR/TE
=4200/56 ms, RARE factor 8, 4 averages, 20 axial slices with
slice thickness of 1 mm, field of view 35635 mm, matrix size
2566256). Calculation of lesion volume was carried out with
Analyze 5.0 (AnalyzeDirect Inc., Lenexa, KS, USA). Hyperintense
ischemic areas in T2-weighted images were assigned with a region
of interest tool. This enables threshold-based segmentation by
connecting all pixels within a specified threshold range and results
in 3D object maps of the whole stroke region. The single volume of
each slice and the total volume of the whole object map were
calculated by the program.
Quantitative real-time PCR
Brains were cut into slices of 250 mm in a cryostat. The ischemic
core was detectable as an area of pallor sharply demarcated from
the adjacent tissue. Tissue was harvested from brain sections by
punching out 5 tissue cylinders with hollow needles (lumen
1.5 mm) from the following brain areas: the ischemic core, the
border of the ischemic lesion and areas corresponding to the
ischemic core and its border in the contralateral non-ischemic
hemisphere (Fig. 1). T2-weighted magnetic resonance images were
used to control the localizations in the appropriate sections. Tissue
samples of the respective areas harvested from 6 consecutive brain
sections were pooled and used for quantitative real-time PCR.
Total RNA was extracted using the NucleoSpin RNA II kit
(Macherey-Nagel, Dueren, Germany). Reverse transcription was
followed by quantitative real-time PCR using an ABI Prism 7000
sequence detection system and SYBR Green I reaction mix
(Applied Biosciences, Darmstadt, Germany). Rat 18S rRNA was
chosen as endogenous control. The following primers were used:
CXC chemokine ligand 1 (CXCL1): F 5-GCACCCAAACC-
GAAGTCATA-3, R 5-ACTTGGGGACACCCTTTAGC-3;
interleukin-6: F 5-ATATGTTCTCAGGGAGATCTTGGAA-3,
R 5-AGTGCATCATCGCTGTTCATACA-3, tumor necrosis
factor (TNF)-alpha: F 5-ACAAGGCTGCCCCGACTA-3, R 5-
CTCCTGGTATGAAGTGGCAAATC-3; 18S rRNA: F 5-CC-
GCAGCTAGGAATAATGGAATA-3, R 5-TCTAGCGGCGC-
AATACGAAT-3. Data were standardized to 18S rRNA expres-
sion and calculated according to the delta-delta Ct method of at
least three independent measurements.
Statistical analysis
Data were analyzed with SPSS 17.0 (SSPS Inc., Chicago, IL,
USA). Data are shown as mean 6 standard error of the mean.
The nonparametric Mann-Whitney-U test was used to detect
significant differences between groups of interest. Mortality rates
were estimated by the Kaplan-Meier method and compared by
log-rank test.
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After 5 days of pre-treatment with the respective doses of
candesartan or aliskiren SBP was effectively lowered close to the
target values of 150 mmHg (protocol 1, Table 1) or 130 mmHg
(protocol 2, Table 2). Blood pressure was not significantly different
between the groups treated with candesartan or aliskiren.
Intraoperative mortality was lower in animals treated with
candesartan (7%) or aliskiren (8%) compared to vehicle-treated
controls (30%). In protocol 2, intraoperative mortality was much
higher (candesartan 40%, aliskiren 26%). A blood pressure of
130 mmHg seems to impair the ability to survive the MCAOR
procedure. Animals that did not survive the MCAOR procedure
were excluded from all further analyses.
The considerable mortality of 33.3% within 24 h after
MCAOR in the vehicle group was reduced to below 10% in all
groups treated with candesartan or aliskiren (Fig. 2, p,0.05). This
low level of mortality persisted until 7 days of follow-up in the
groups treated to 130 mmHg. Mortality was not different between
the groups treated with candesartan or aliskiren. No animal died
during or after sham intervention.
Neurological outcome 24 h post-ischemia was not significantly
different between any of the groups (Table 1 and Fig. 3). However,
7 days after MCAOR the neurological score was significantly
better in animals treated with aliskiren compared to those treated
with candesartan (Fig. 3, p,0.05). All vehicle-treated animals had
cerebral seizures after MCAOR. In contrast, none of the animals
treated with candesartan or aliskiren experienced seizures.
Infarct size 24 h and 7 days after MCAOR was not significantly
different between the groups (Fig. 4). However, there was a trend
in favor of aliskiren at all time points (relative reduction of infarct
size 13–33%).
Gene expression of CXCL1, interleukin-6 and TNF-alpha was
upregulated in ischemic brain areas of dTGR (Fig. 5). Relative
gene expression of CXCL1, interleukin-6 and TNF-alpha was
significantly reduced in the ischemic core of dTGR treated with
aliskiren (p,0.05). In contrast, in the ischemic border zone there
was a significant reduction of CXCL1 gene expression in animals
treated with candesartan (p,0.01). Candesartan and aliskiren did
not affect baseline gene expression in the non-ischemic contralat-
eral hemisphere.
Mean body weight and brain weight of all groups are shown in
Tables 1 and 2. Body weight decreased significantly 24 h after
MCAOR and also after sham intervention. Animals treated with
candesartan or aliskiren did not loose weight after the sham
intervention. After MCAOR, animals treated with aliskiren lost
slightly less weight, however body weight was not significantly
different between the groups treated with candesartan or aliskiren.
Brain weight did not differ between the groups.
Discussion
The present study investigated the neuroprotective effects of the
renin inhibitor aliskiren for the first time. Aliskiren was compared
to candesartan in a hypertensive animal model (dTGR) of cerebral
ischemia (MCAOR), with respect to mortality, neurological
outcome, infarct volume and inflammatory gene regulation in
brain tissue. Treatment with candesartan or aliskiren equally
reduced mortality by about 75%, and prevented 100% of cerebral
seizures after MCAOR. Aliskiren-treated animals showed a better
neurological outcome 7 days post-ischemia, compared to those
treated with candesartan. Only aliskiren was able to reduce gene
expression of CXCL1, interleukin-6 and TNF-alpha in the
ischemic core. Candesartan reduced CXCL1 gene expression
within the border of the ischemic lesion.
Ischemic stroke triggers an intense inflammatory reaction that
progresses for several days and involves a broad range of pro-
inflammatory mediators previously demonstrated to worsen
ischemic brain injury, to increase infarct size and to impair
neurological outcome [26]. The present study analyzed some of
those mediators in brain tissue after MCAOR.
CXCL1 belongs to a superfamily of small proteins that exhibit
chemo-attractant properties for the recruitment of leucocytes to
sites of injury or inflammation [27]. The results of this study
confirm previous findings from animal models and humans, that
CXCL1 is increased in cerebral ischemia [28]. Pre-treatment with
candesartan or aliskiren attenuated this increase of CXCL1
expression 24 h post-ischemia. It remains unclear why candesar-
tan exerted its effects in the ischemic border zone and aliskiren in
the ischemic core only.
The pro-inflammatory cytokine TNF-alpha has been previously
reported to be upregulated during cerebral ischemia [29,30]. This
is in line with results of our study. Preclinical studies in animal
models of stroke suggest beneficial effects of interventions that
decrease the inflammatory reaction of the postischemic brain [31].
The administration of TNF-alpha antibodies was able to reduce
the infarct volume in ischemic mouse brain [32]. In the present
study aliskiren attenuated the expression of TNF-alpha in the
ischemic core.
The effect of aliskiren on the measured markers of local
inflammation (CXCL1, interleukin-6 and TNF-alpha) seemed
more pronounced in comparison to candesartan. However, it
should be noted, that effects on those cytokines might not be
representative for the inflammatory reaction as a whole, nor do
they necessarily translate into effects on endpoint such as
neurological outcome and infarct size. Ischemia-induced inflam-
mation plays a critical role in the late stages of cerebral ischemic
injury [33]. This may explain our findings that aliskiren does not
significantly decrease infarct size 24 h after MCAOR but has an
effect on neurological outcome on day 7.
Figure 1. Representative T2-weighted, axial magnetic reso-
nance image 24 h after middle cerebral artery occlusion with
reperfusion. The hyperintensity corresponds to the ischemic area.
Tissue was obtained from the ischemic core (black circles), the border of
the ischemic lesion (black squares) and areas corresponding to the
ischemic core (white circles) and its border (white squares) in the
contralateral, non-ischemic hemisphere.
doi:10.1371/journal.pone.0015052.g001
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PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e15052Angiotensin II itself, besides its effects on blood pressure, has also
beencharacterizedasapro-inflammatorymediator[34].Angiotensin
type 2 receptor blockers possess anti-inflammatory properties [35],
however, the cerebral protection of these substances also involves
other mechanisms [36]. Anti-inflammatory properties of renin
inhibitors have so far been investigated in few studies only [37–39].
Whether the suppression of cerebral seizures by both cande-
sartan and aliskiren is mediated by reduced inflammation, reduced
blood pressure or other mechanisms remains to be investigated.
In contrast to previous reports [40–44] candesartan did not
significantly reduce the infarct size in the dTGR model. This might
be partly due to mortality bias. The large proportion of animals that
Figure 2. Mortality of double transgenic rats after middle
cerebral artery occlusion with reperfusion. Groups according to
treatment (Veh, vehicle, Cand, candesartan, Alis, aliskiren), systolic
blood pressure and duration of follow-up. There was no mortality in the
groups with sham intervention. Absolute numbers are given at the
bottom of the columns. Mortality rates were compared by log-rank test.
*p,0.05 vs. treated animals.
doi:10.1371/journal.pone.0015052.g002
Figure 3. Neurological score in double transgenic rats after
middle cerebral artery occlusion with reperfusion (MCAOR) or
sham intervention. Animals were pre-treated to a systolic blood
pressure of 130 mmHg starting 5 days prior to intervention. Data are
means 6 standard error of the mean. n=9-13 per group. The Mann-
Whitney-U test was used for comparisons. *p,0.05 vs. MCAOR
Candesartan.
doi:10.1371/journal.pone.0015052.g003
Table 2. Systolic blood pressure (SBP), body weight and brain weight of double transgenic rats before and after middle cerebral
artery occlusion with reperfusion (MCAOR) or sham intervention; protocol 2 with blood pressure target of 130 mmHg and 7 days of
follow-up.
Sham intervention MCAOR
Candesartan Aliskiren Candesartan Aliskiren
N (after intervention) 9 9 12 14
N (at study end) 9 9 11 13
SBP before minipump (mmHg) 177 6 5 180 6 5 187 6 4 182 6 5
SBP before intervention (mmHg) 135 6 3 132 6 4 130 6 4 132 6 3
Weight before minipump (g) 179 6 4 183 6 4 184 6 3 179 6 5
Weight before intervention (g) 214 6 3 219 6 5 220 6 3 222 6 5
Weight 24 h after intervention (g) 211 6 3 215 6 3 194 6 3* 197 6 5*
Weight 48 h after intervention (g) 222 6 3 225 6 3 202 6 3 205 6 7
Weight 7 d after intervention (g) 257 6 4 259 6 5 209 6 14 223 6 10
Brain weight 24 h after intervention (g) 1.82 6 0.01 1.83 6 0.01 1.75 6 0.02 1.78 6 0.02
Differences between the treatment groups (candesartan vs. aliskiren) were not statistically significant. There was no vehicle group in this protocol because untreated
animals do not survive 48 h after MCAOR.
Data are means 6 standard error of the mean.
The Mann-Whitney-U test was used for comparisons.
*p,0.01 vs. same group before intervention.
doi:10.1371/journal.pone.0015052.t002
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33.3% within 24 h after MCAOR) most probably had larger
infarcts than the surviving animals. The infarct size in the vehicle
group came probably close to the maximal survivable size. In
addition, the model of dTGR, with its strongly upregulated renin-
angiotensin system might behave different from other models. This
study is the first to describe experimental stroke in dTGR.
A significant part of the initial infarct size is due to reversible
edema. This is reflected by the finding that 7 days post-ischemia,
when the edema has partially resolved, the infarct size becomes
considerably smaller. Because untreated dTGR do not survive 48 h
after MCAOR there is no vehicle group available for comparison at
later stages. We thus cannot determine whether treatment with
candesartan or aliskiren reduces the infarct size after the resolution of
edema. This is a limitation of the dTGR model. However, because
aliskiren specifically blocks human renin, this study could be carried
out only in dTGR expressing human renin and human angioten-
sinogen genes. There is no better animal model available at present.
In conclusion, head-to-head comparison suggests that aliskiren
is at least as effective as candesartan, regarding the endpoints of
mortality, neurological outcome (including seizures) and infarct
size in dTGR after MCAOR. On day 7, there is an even better
neurological outcome in the group treated with aliskiren. This
might be partly explained by primary anti-inflammatory mecha-
nisms that appear stronger in the aliskiren-treated group. Infarct
size tended to be smaller in the aliskiren group at all time points,
with the highest reduction rate of 33% after 7 days. However, this
difference does not reach statistical significance. The beneficial
effects of aliskiren were independent of blood pressure reduction
since equal blood pressure levels were achieved by the respective
doses of candesartan and aliskiren. It is a limitation of the study
that cerebral perfusion pressure was not directly measured.
However, most likely cerebral perfusion pressure will be strongly
correlated to the systemic blood pressure since there is an
impairment of cerebral autoregulation in acute stroke.
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Figure 5. Relative expression of inflammatory genes in brain
tissue of double transgenic rats 24 h after middle cerebral
artery occlusion with reperfusion. Tissue was obtained from the
ischemic core, the border of the ischemic lesion and corresponding
areas in the contralateral, non-ischemic hemisphere (‘‘core’’ and
‘‘border’’). Animals were pre-treated to a systolic blood pressure of
150 mmHg or received vehicle. Data are means 6 standard error of the
mean. n=11-14 per group. The Mann-Whitney-U test was used for
comparisons. *p,0.05, **p,0.01, vs. vehicle,
#p,0.05 vs. vehicle and
candesartan.
doi:10.1371/journal.pone.0015052.g005
Figure 4. Infarct size determined by magnetic resonance
imaging in double transgenic rats after middle cerebral artery
occlusion with reperfusion. Groups according to treatment (Veh,
vehicle, Cand, candesartan, Alis, aliskiren), systolic blood pressure and
duration of follow-up. Differences between the treatment groups were
not statistically significant. Data are means 6 standard error of the
mean. n=11-14 per group.
doi:10.1371/journal.pone.0015052.g004
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